Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DOPA PET Imaging for Biodistribution and Safety
NCT03042416Phase 3Completed
- Sponsor
- University of Alberta
- Start
- Jun 2017
- Primary completion
- Mar 2021
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Fluorodopa F 18 in congenital hyperinsulinism (HI), neuroblastoma, Neuroendocrine Neoplasm (NEN) and 2 more, sponsored by University of Alberta. Primary endpoint: Immediate safety evaluation at 1 hour. Started Jun 2017; status: completed.
02
Drugs
Fluorodopa F 18
03
Conditions
congenital hyperinsulinism (HI)neuroblastomaNeuroendocrine Neoplasm (NEN)Parkinson's disease (PD)glioma
Beyond the preview
Go deeper on NCT03042416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042416.